The 539 lipizones are a spatial map of adult mouse-brain lipid signatures, not yet a demonstrated developmental or disease time series. Separate human studies show that brain lipid composition changes substantially with age and is altered in autism, schizophrenia, Down syndrome, and Alzheimer’s-related biology, making remodeling plausible but leaving the fate of each lipizone unresolved.
Two lenses on the same evidence. Source weight and the primary source ratio show what each rests on.
Alternative
Source weight 56%
Lens adapted to this topic: What the map may reveal next
A more exploratory reading treats the 539 lipizones as potentially dynamic chemical territories rather than fixed anatomical units. Developmental lipid programs, disease-related shifts in myelin and cell composition, or altered connectivity could change territory intensity or boundaries. This interpretation is grounded in observed lipid remodeling, but it remains an inference until matched atlases directly compare ages, disease models, and controls using the same spatial method.
If lipid signatures function as molecular addresses, developmental remodeling could alter the chemical definition of some territories without changing gross anatomy.
White matter’s previously hidden lipid heterogeneity suggests that disease-related myelin or glial changes could affect lipizone boundaries or subdivisions.
The atlas’s regional signatures may be sensitive to changing cell-type composition, because hundreds of human lipid features track myelin or cell-type characteristics.
Observed disease lipid alterations establish a plausible mechanism for lipizone remodeling, but the supplied studies do not directly map the 539 regions across disease states.